Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Veradermics, Incorporated ( (MANE) ) has provided an announcement.
On April 27, 2026, Veradermics reported positive topline results from Part A of its Phase 2/3 Study 302 evaluating VDPHL01 in 519 men with mild-to-moderate pattern hair loss. The oral extended-release minoxidil met all primary and key secondary endpoints, delivering rapid, robust hair growth and high rates of patient- and investigator-reported improvement, with statistically significant benefits over placebo by Month 2 and sustained through Month 6.
The treatment showed a favorable safety and tolerability profile with overall adverse event rates similar to placebo, no treatment-related serious cardiac events, and low discontinuation rates, underscoring a potentially differentiated risk-benefit profile versus existing options. Veradermics believes these data, together with its broader pivotal program including the ongoing Phase 3 Study 304 in men and Study 306 in women, could position VDPHL01 as the first FDA-approved non-hormonal oral therapy for pattern hair loss in decades, a milestone that could materially influence the competitive landscape and address significant unmet demand in a large aesthetics market.
The most recent analyst rating on (MANE) stock is a Buy with a $85.00 price target. To see the full list of analyst forecasts on Veradermics, Incorporated stock, see the MANE Stock Forecast page.
More about Veradermics, Incorporated
Veradermics, Inc. is a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative, non-hormonal therapeutics for pattern hair loss in both men and women. The company targets high-prevalence aesthetic dermatology conditions, aiming to build a focused portfolio of hair loss treatments in a market projected to reach roughly $30 billion by 2028.
Its lead candidate, VDPHL01, is a proprietary extended-release oral minoxidil tablet designed to optimize efficacy and safety for pattern hair loss, with patent protection extending at least to 2043. Veradermics’ development program spans multiple Phase 2/3 and Phase 3 trials in male and female patients, positioning it as a specialized player in the rapidly growing hair loss therapeutics segment.
Average Trading Volume: 445,447
For detailed information about MANE stock, go to TipRanks’ Stock Analysis page.